Company intelligence / Profile preview
Dignify Therapeutics
Research Triangle Park, North Carolina, United Statesdignifytherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Dignify Therapeutics is developing "on-demand" drugs for bladder and bowel emptying. Their lead candidates DTI-301 and DTI-117 are in preclinical development. DTI-301 is a rectal suppository that induces defecation within 5-10 minutes, while DTI-117 is being developed for on-demand emptying of both bladder and bowel.
- Therapeutic areas
- GastroenterologyMen's HealthUrologyEndocrinologyNeurology
- Modalities
- Small moleculesChemical drugsSynthetic peptide
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Praxis SCI Accelerate ProgramAayam Therapeutics
Beyond the preview
Go deeper on Dignify Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dignify Therapeutics.